[P02BB01, trichlorfon, The therapeutic efficacy of Doxepin can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Antipyrine.]
[J01GA01, streptomycin, Doxepin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01CG01, sulbactam, Doxepin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Doxepin may decrease the hypoglycemic activities of Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Doxepin can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, Doxepin may decrease the hypoglycemic activities of Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Doxepin can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Doxepin can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Doxepin can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, Doxepin may decrease the hypoglycemic activities of Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Sulindac.]
[N05AL01, sulpiride, Doxepin may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AE07, suprofen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Suprofen.]
[A10BB04, glibornuride, Doxepin may decrease the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, Doxepin may decrease the hypoglycemic activities of Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Azapropazone.]
[N06DA01, tacrine, The metabolism of Doxepin can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Doxepin.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01CB02, teniposide, The metabolism of Doxepin can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Doxepin.]
[B01AE07, dabigatran etexilate, Doxepin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The metabolism of Doxepin can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of sedation and somnolence can be increased when Doxepin is combined with Tetrabenazine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N05AE05, lurasidone, Doxepin may increase the hypotensive activities of Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L04AX02, thalidomide, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Doxepin.]
[P02CA02, thiabendazole, The metabolism of Doxepin can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Eribulin.]
[R06AD03, thiethylperazine, The serum concentration of Doxepin can be increased when it is combined with Thiethylperazine.]
[L01AC01, thiotepa, The therapeutic efficacy of Doxepin can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, The metabolism of Doxepin can be increased when combined with Thiopental.]
[N05AB08, thioproperazine, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.]
[N05AC02, thioridazine, Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Doxepin.]
[B02AB01, aprotinin, The therapeutic efficacy of Doxepin can be decreased when used in combination with Aprotinin.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Doxepin is combined with Moxisylyte.]
[B03AB03, sodium ironedetate, Doxepin can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CJ01, thyrotropin, The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin is combined with Doxepin.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[B01AC05, ticlopidine, The metabolism of Doxepin can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Doxepin is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Doxepin.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[S01AA12, tobramycin, Doxepin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Doxepin may decrease the hypoglycemic activities of Tolazamide.]
[M02AX02, tolazoline, Tolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[V04CA01, tolbutamide, Doxepin may decrease the hypoglycemic activities of Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Tolmetin.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Doxepin is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the serotonergic activities of Doxepin.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Doxepin.]
[L01XF01, tretinoin, The metabolism of Doxepin can be decreased when combined with Tretinoin.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Doxepin can be decreased when used in combination with Demecarium.]
[A16AX12, trientine, Doxepin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05AA05, triflupromazine, The serum concentration of Doxepin can be increased when it is combined with Triflupromazine.]
[N04AA01, trihexyphenidyl, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The serum concentration of Doxepin can be increased when it is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Doxepin.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N06AA06, trimipramine, Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[R06AC04, tripelennamine, The metabolism of Doxepin can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A03BB01, butylscopolamine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Doxepin can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Doxepin can be decreased when combined with Vilazodone.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Tropicamide is combined with Doxepin.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C09CA09, azilsartan medoxomil, Doxepin may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Doxepin.]
[L01FX04, ipilimumab, Doxepin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[S01AA05, tyrothricin, The therapeutic efficacy of Doxepin can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Vandetanib.]
[R02AA14, oxyquinoline, Doxepin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Doxepin can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, Doxepin may decrease the hypoglycemic activities of Linagliptin.]
[J05AP03, boceprevir, The metabolism of Doxepin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Doxepin can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, Doxepin can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AA28, vancomycin, Doxepin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[B01AF01, rivaroxaban, Doxepin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Doxepin.]
[B01AC24, ticagrelor, The metabolism of Doxepin can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[N06AX09, viloxazine, The metabolism of Doxepin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Doxepin can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Doxepin may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Doxepin.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Doxepin is combined with Warfarin.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Doxepin is combined with Xenon.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Doxepin can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[J05AE02, indinavir, Doxepin can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01EC01, vemurafenib, The serum concentration of Doxepin can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[B06AC02, icatibant, Doxepin may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Doxepin can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Doxepin can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Doxepin can be decreased when combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Doxepin.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Doxepin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Doxepin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Doxepin may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Atenolol may increase the orthostatic hypotensive activities of Doxepin.]
[L03AB11, peginterferon alfa-2a, The metabolism of Doxepin can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Doxepin can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01FA01, atropine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Doxepin.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Doxepin.]
[B03XA04, peginesatide, Doxepin may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L04AX01, azathioprine, The metabolism of Doxepin can be decreased when combined with Azathioprine.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[G04BE10, avanafil, Doxepin may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of CNS depression and hypotonia can be increased when Baclofen is combined with Doxepin.]
[A08AA11, lorcaserin, The metabolism of Doxepin can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Doxepin is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Doxepin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Doxepin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Doxepin can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Doxepin.]
[L01EA04, bosutinib, Doxepin can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA31, teriflunomide, The serum concentration of Doxepin can be decreased when it is combined with Teriflunomide.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Doxepin.]
[L01EX05, regorafenib, The metabolism of Doxepin can be decreased when combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Doxepin can be increased when combined with Barbital.]
[D02BA02, octinoxate, Doxepin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, Doxepin can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Doxepin.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N04BD02, rasagiline, Rasagiline may increase the serotonergic activities of Doxepin.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Doxepin is combined with Lercanidipine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06DA02, donepezil, The therapeutic efficacy of Doxepin can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AC06, thonzylamine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Doxepin can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Doxepin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Doxepin.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Doxepin.]
[V08CA11, gadofosveset, Doxepin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Doxepin.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Doxepin.]
[A16AX08, teduglutide, Doxepin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Doxepin is combined with Bencyclane.]
[A10BH04, alogliptin, Doxepin may decrease the hypoglycemic activities of Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Doxepin can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[G03XC05, ospemifene, The metabolism of Doxepin can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Benorilate.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BK02, canagliflozin, Doxepin may decrease the hypoglycemic activities of Canagliflozin.]
[J01MA15, gemifloxacin, The metabolism of Doxepin can be decreased when combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Doxepin can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The metabolism of Doxepin can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Doxepin can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The risk or severity of Cardiac Arrhythmia can be increased when Tiratricol is combined with Doxepin.]
[A10AE05, insulin detemir, Doxepin may decrease the hypoglycemic activities of Insulin detemir.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Doxepin.]
[L03AA12, ancestim, Doxepin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Doxepin can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L04AA18, everolimus, The metabolism of Doxepin can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Doxepin can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Benzydamine.]
[L01EE01, trametinib, Doxepin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[V09AX05, florbetapir F-18, Doxepin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[B03AB04, ferric hydroxide, Doxepin can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Doxepin is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of hypotension can be increased when Doxepin is combined with Bepridil.]
[C02KX05, riociguat, Doxepin may decrease the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, Doxepin may decrease the hypoglycemic activities of Lixisenatide.]
[C02KX04, macitentan, Doxepin may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Doxepin.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[D01AC18, luliconazole, The serum concentration of Doxepin can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Doxepin can be decreased when combined with Simeprevir.]
[V03AE05, sucroferric oxyhydroxide, Doxepin can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AP08, sofosbuvir, Doxepin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BK01, dapagliflozin, Doxepin may decrease the hypoglycemic activities of Dapagliflozin.]
[C01CA27, droxidopa, Doxepin may increase the vasopressor activities of Droxidopa.]
[C07AB04, acebutolol, Acebutolol may increase the orthostatic hypotensive activities of Doxepin.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A16AA07, metreleptin, The metabolism of Doxepin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Doxepin can be increased when combined with Apremilast.]
[L02BG02, formestane, Doxepin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[N07CA01, betahistine, The therapeutic efficacy of Betahistine can be decreased when used in combination with Doxepin.]
[A16AA06, betaine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Betaine.]
[S01ED02, betaxolol, Betaxolol may increase the orthostatic hypotensive activities of Doxepin.]
[V03AB34, fomepizole, Doxepin may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Doxepin.]
[A10BJ04, albiglutide, Doxepin may decrease the hypoglycemic activities of Albiglutide.]
[L04AC11, siltuximab, The metabolism of Doxepin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Doxepin can be decreased when combined with Ceritinib.]
[A03BA03, hyoscyamine, Doxepin may increase the anticholinergic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Doxepin is combined with Acenocoumarol.]
[L01XH04, belinostat, The metabolism of Doxepin can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BK03, empagliflozin, Doxepin may decrease the hypoglycemic activities of Empagliflozin.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Doxepin.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Doxepin is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N05CM19, suvorexant, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Doxepin can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Doxepin can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N05AA04, acepromazine, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.]
[V04CX03, methacholine, Doxepin may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Doxepin.]
[A10BJ05, dulaglutide, Doxepin may decrease the hypoglycemic activities of Dulaglutide.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Doxepin is combined with Naloxegol.]
[N04AA02, biperiden, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Doxepin.]
[V03AE08, ferric citrate, Doxepin can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Doxepin.]
[S03AA06, gentamicin, Doxepin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Doxepin.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Doxepin is combined with Dicoumarol.]
[B01AF03, edoxaban, Doxepin may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Doxepin may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Doxepin can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Doxepin can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Doxepin can be decreased when combined with Acetaminophen.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[A03AA09, difemerine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Doxepin is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Doxepin can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Doxepin is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Doxepin can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Doxepin.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BF01, acarbose, Doxepin may decrease the hypoglycemic activities of Acarbose.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10AE06, insulin degludec, Doxepin may decrease the hypoglycemic activities of Insulin degludec.]
[N05AB07, acetophenazine, The serum concentration of Doxepin can be increased when it is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Doxepin can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Doxepin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Doxepin.]
[J02AC05, isavuconazole, The metabolism of Doxepin can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Doxepin can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Doxepin.]
[L01XG03, ixazomib, Doxepin may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Doxepin may decrease the antihypertensive activities of Selexipag.]
[A10BB31, acetohexamide, Doxepin may decrease the hypoglycemic activities of Acetohexamide.]
[G04CA01, alfuzosin, Doxepin may increase the hypotensive activities of Alfuzosin.]
[M04AB05, lesinurad, Doxepin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Alminoprofen.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01XX52, venetoclax, The metabolism of Doxepin can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N04BC01, bromocriptine, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Doxepin may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Doxepin is combined with Amlodipine.]
[N05AX17, pimavanserin, Doxepin may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M02AA09, bufexamac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Bufexamac.]
[A05AA04, obeticholic acid, The metabolism of Doxepin can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C07AA19, bupranolol, Bupranolol may increase the orthostatic hypotensive activities of Doxepin.]
[N07BC01, buprenorphine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Buserelin.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Doxepin can be decreased when combined with Rabeprazole.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Doxepin is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Doxepin.]
[S01GX07, azelastine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Doxepin can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Azithromycin.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Doxepin.]
[L01EF02, ribociclib, The metabolism of Doxepin can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Doxepin.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Doxepin.]
[A06AH05, naldemedine, Doxepin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of sedation and somnolence can be increased when Doxepin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Doxepin can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06BC01, caffeine, The metabolism of Doxepin can be decreased when combined with Caffeine.]
[C09AA07, benazepril, Doxepin may decrease the antihypertensive activities of Benazepril.]
[A10BX06, benfluorex, Doxepin may decrease the hypoglycemic activities of Benfluorex.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[P01CA02, benznidazole, Doxepin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Doxepin.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Doxepin can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The risk or severity of Cardiac Arrhythmia can be increased when Benzylthiouracil is combined with Doxepin.]
[N07XX13, valbenazine, Doxepin may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Doxepin can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Doxepin can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the serotonergic activities of Doxepin.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Delafloxacin.]
[D01AC10, bifonazole, Doxepin can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BC06, capecitabine, The metabolism of Doxepin can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Doxepin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Vorinostat.]
[A02BX12, bismuth subnitrate, Doxepin may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, Bisoprolol may increase the orthostatic hypotensive activities of Doxepin.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Doxepin.]
[J05AG03, efavirenz, The metabolism of Doxepin can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C07AA17, bopindolol, Bopindolol may increase the orthostatic hypotensive activities of Doxepin.]
[N04AA11, bornaprine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[S01BC11, bromfenac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Bromfenac.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Doxepin can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Doxepin is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Bumadizone.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J05AX18, letermovir, The metabolism of Doxepin can be increased when combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, Doxepin may decrease the hypoglycemic activities of Semaglutide.]
[N01BX04, capsaicin, The metabolism of Doxepin can be increased when combined with Capsaicin.]
[A10BK04, ertugliflozin, Doxepin may decrease the hypoglycemic activities of Ertugliflozin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Acrivastine.]
[C09AA01, captopril, Doxepin may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Doxepin.]
[L02BB05, apalutamide, The serum concentration of Doxepin can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Doxepin can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Doxepin.]
[A03AA03, camylofine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The risk or severity of Cardiac Arrhythmia can be increased when Carbimazole is combined with Doxepin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L03AB06, interferon alfa-n1, The metabolism of Doxepin can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Doxepin.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Doxepin.]
[B02BX08, avatrombopag, The metabolism of Doxepin can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Doxepin may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Doxepin can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Encorafenib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Doxepin.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01GB14, plazomicin, Doxepin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be decreased when used in combination with Doxepin.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Doxepin.]
[L01XX62, ivosidenib, The metabolism of Doxepin can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Doxepin.]
[A16AX14, migalastat, Doxepin may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Doxepin can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Doxepin can be decreased when combined with Tecovirimat.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Doxepin.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BB06, carbutamide, Doxepin may decrease the hypoglycemic activities of Carbutamide.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[D08AE05, chloroxylenol, Doxepin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Doxepin.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Inotersen.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxepin.]
[R03BB08, revefenacin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Doxepin can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Doxepin can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Doxepin can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Doxepin is combined with Amifampridine.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Doxepin.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Cibenzoline.]
[C09AA08, cilazapril, Doxepin may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Cilostazol.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[P02BX04, triclabendazole, The metabolism of Doxepin can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Doxepin.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Doxepin is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Doxepin can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Doxepin.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Doxepin.]
[N05BA09, clobazam, The metabolism of Doxepin can be decreased when combined with Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Doxepin.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C09CA06, candesartan, Doxepin may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Doxepin can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Doxepin can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N05AA06, cyamemazine, The serum concentration of Doxepin can be increased when it is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[S01AA27, cefuroxime, Doxepin can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Doxepin.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Doxepin.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Entrectinib.]
[N07XX11, pitolisant, The therapeutic efficacy of Pitolisant can be decreased when used in combination with Doxepin.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Doxepin.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Doxepin.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The serum concentration of Yohimbine can be increased when it is combined with Doxepin.]
[A10AE03, insulin, regular, pork, Doxepin may decrease the hypoglycemic activities of Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Doxepin.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Doxepin.]
[G03AC09, desogestrel, The metabolism of Doxepin can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Doxepin.]
[N03AX25, cenobamate, The serum concentration of Doxepin can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Doxepin can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Doxepin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AB02, dexchlorpheniramine, The metabolism of Doxepin can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Doxepin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Doxepin is combined with Dezocine.]
[L01EX18, avapritinib, The metabolism of Doxepin can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AX21, diacetylrhein, The metabolism of Doxepin can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Doxepin can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Doxepin can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Doxepin can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Doxepin.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Doxepin.]
[R02AA03, dichlorobenzyl alcohol, Doxepin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Doxepin may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Doxepin is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Doxepin can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Doxepin is combined with Clevidipine.]
[C01BD07, dronedarone, Dronedarone may increase the QTc-prolonging activities of Doxepin.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S03AA08, chloramphenicol, The metabolism of Doxepin can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C02AA06, methoserpidine, Doxepin may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Doxepin.]
[A03AA08, dihexyverine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Doxepin can be decreased when combined with Capmatinib.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Doxepin.]
[G04BD09, trospium, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Droxicam.]
[V08CA05, mangafodipir, Doxepin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Doxepin.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C08CA17, levamlodipine, The risk or severity of hypotension can be increased when Doxepin is combined with Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Doxepin can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L04AC19, satralizumab, The serum concentration of Doxepin can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Doxepin is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Doxepin can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Doxepin can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA06, chlorotrianisene, The serum concentration of Doxepin can be increased when it is combined with Chlorotrianisene.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[A10BB02, chlorpropamide, Doxepin may decrease the hypoglycemic activities of Chlorpropamide.]
[N05AF03, chlorprothixene, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A11CC05, cholecalciferol, The metabolism of Doxepin can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Ethenzamide.]
[N02BA03, choline salicylate, Doxepin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Doxepin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Doxepin can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Doxepin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Doxepin is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Doxepin can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Doxepin can be decreased when combined with Tepotinib.]
[V03AF12, trilaciclib, The metabolism of Doxepin can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Fenbufen.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Doxepin.]
[C01CA19, fenoldopam, Doxepin may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Doxepin is combined with Fenozolone.]
[V08CA07, ferric ammonium citrate, Doxepin can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Doxepin can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Doxepin can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Doxepin can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Doxepin can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Doxepin can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Doxepin can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Doxepin is combined with Finasteride.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Flumequine.]
[N02BG07, flupirtine, Doxepin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Doxepin.]
[A10AF01, insulin, regular, human, Doxepin may decrease the hypoglycemic activities of Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Doxepin.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Doxepin can be increased when it is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Doxepin may decrease the antihypertensive activities of Dasiglucagon.]
[G03GA06, follitropin beta, The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Doxepin.]
[B03AB10, ferric maltol, Doxepin can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The metabolism of Doxepin can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of hypotension can be increased when Doxepin is combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Doxepin can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The therapeutic efficacy of Sotorasib can be decreased when used in combination with Doxepin.]
[S03AA07, ciprofloxacin, The metabolism of Doxepin can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Doxepin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Doxepin can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Doxepin is combined with Fexinidazole.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be decreased when combined with Doxepin.]
[H01AC09, lonapegsomatropin, The metabolism of Doxepin can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Doxepin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Doxepin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Doxepin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BB12, glimepiride, Doxepin may decrease the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Doxepin may decrease the hypoglycemic activities of Gliquidone.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Doxepin.]
[J01FF01, clindamycin, Doxepin may increase the neurotoxic activities of Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Doxepin can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Doxepin can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Doxepin.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Doxepin.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Doxepin.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Doxepin.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Doxepin.]
[C01EB24, mavacamten, The serum concentration of Doxepin can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[A10BX16, tirzepatide, Doxepin may decrease the hypoglycemic activities of Tirzepatide.]
[J02AC06, oteseconazole, Doxepin can cause a decrease in the absorption of Oteseconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC08, vonoprazan, The metabolism of Doxepin can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M02AA08, felbinac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Felbinac.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05AH02, clozapine, Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[A10BX01, guar gum, Doxepin may decrease the hypoglycemic activities of Guar gum.]
[A10BK06, sotagliflozin, Doxepin may decrease the hypoglycemic activities of Sotagliflozin.]
[J01GB12, arbekacin, Doxepin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[H01AC08, somatrogon, The metabolism of Doxepin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Doxepin may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Doxepin can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Doxepin is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M04AC01, colchicine, Doxepin may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Doxepin is combined with Homatropine.]
[J01XB01, colistin, Doxepin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L04AA13, leflunomide, The serum concentration of Doxepin can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BX03, nateglinide, Doxepin may decrease the hypoglycemic activities of Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Imidazole salicylate.]
[H01AC03, mecasermin, Doxepin may decrease the hypoglycemic activities of Mecasermin.]
[A10AE04, insulin glargine, Doxepin may decrease the hypoglycemic activities of Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Doxepin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Doxepin.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Indobufen.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J05AB14, valganciclovir, Doxepin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Doxepin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Doxepin may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Doxepin may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Doxepin may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Doxepin may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Valdecoxib.]
[H01AX01, pegvisomant, The therapeutic efficacy of Doxepin can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, Doxepin may increase the vasopressor activities of Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Parecoxib.]
[J02AC02, itraconazole, Doxepin can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AD03, acyclovir, The metabolism of Doxepin can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Emedastine.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Doxepin can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Doxepin can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Doxepin can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, The risk or severity of hypotension can be increased when Doxepin is combined with Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Doxepin.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N07BC04, lofexidine, The therapeutic efficacy of Doxepin can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Doxepin can be decreased when combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Lonazolac.]
[R06AX13, loratadine, Doxepin may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C09AA03, lisinopril, Doxepin may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Doxepin.]
[C08CA11, manidipine, The metabolism of Doxepin can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Doxepin is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may increase the orthostatic hypotensive activities of Doxepin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Doxepin.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Adenosine.]
[N04AA03, methixene, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Doxepin is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the sedative and stimulatory activities of Doxepin.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01BC10, nepafenac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Nepafenac.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, Doxepin may decrease the hypoglycemic activities of Miglitol.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Doxepin.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Doxepin can be decreased when combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the serotonergic activities of Doxepin.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Doxepin.]
[S01XA18, cyclosporine, The metabolism of Doxepin can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the serotonergic activities of Doxepin.]
[N06BA07, modafinil, The metabolism of Doxepin can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Doxepin.]
[C10AA07, rosuvastatin, The metabolism of Doxepin can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Mofebutazone.]
[S01XA21, cysteamine, Doxepin can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Doxepin can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Doxepin.]
[J05AF10, entecavir, The metabolism of Doxepin can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Doxepin.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Etoricoxib.]
[L01AX04, dacarbazine, The metabolism of Doxepin can be decreased when combined with Dacarbazine.]
[G03XA01, danazol, The metabolism of Doxepin can be decreased when combined with Danazol.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J04BA02, dapsone, The metabolism of Doxepin can be decreased when combined with Dapsone.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C02CC04, debrisoquin, Doxepin may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Nabumetone.]
[N07BB05, nalmefene, Doxepin may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be decreased when used in combination with Doxepin.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N06AX06, nefazodone, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01DX16, nicorandil, The therapeutic efficacy of Nicorandil can be decreased when used in combination with Doxepin.]
[L02BB02, nilutamide, The metabolism of Doxepin can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Doxepin.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Doxepin.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Doxepin is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Doxepin is combined with Escitalopram.]
[G04BD08, solifenacin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Doxepin can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia and water intoxication can be increased when Doxepin is combined with Desmopressin.]
[V04CH02, indigo carmine, Doxepin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C09XA02, aliskiren, Doxepin may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S03BA01, dexamethasone, The metabolism of Doxepin can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N04AA08, dexetimide, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Doxepin.]
[A03AA01, oxyphencyclimine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Doxepin can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, Doxepin can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the sedative and stimulatory activities of Doxepin.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Doxepin is combined with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Doxepin can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Doxepin can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Doxepin is combined with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Doxepin.]
[P03AC04, permethrin, Doxepin may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[V03AH01, diazoxide, Doxepin may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R05DA08, pholcodine, Doxepin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Doxepin.]
[A03AA07, dicyclomine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C02DG01, pinacidil, Doxepin may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Doxepin is combined with Pinaverium.]
[A10BG03, pioglitazone, Doxepin may decrease the hypoglycemic activities of Pioglitazone.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A03AB14, pipenzolate, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, Doxepin can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Doxepin.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may decrease the sedative and stimulatory activities of Doxepin.]
[L02AA01, diethylstilbestrol, The metabolism of Doxepin can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of hypotension can be increased when Doxepin is combined with Isradipine.]
[D07XC04, diflucortolone, Doxepin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Digitoxin.]
[C01AA05, digoxin, Doxepin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, The metabolism of Doxepin can be decreased when combined with Dihydralazine.]
[L02AA02, polyestradiol phosphate, The serum concentration of Doxepin can be increased when it is combined with Polyestradiol phosphate.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Doxepin is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Doxepin is combined with Hydromorphone.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J05AE08, atazanavir, Doxepin can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Doxepin.]
[H03BC01, potassium perchlorate, The risk or severity of Cardiac Arrhythmia can be increased when Potassium perchlorate is combined with Doxepin.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C08DB01, diltiazem, The risk or severity of hypotension can be increased when Doxepin is combined with Diltiazem.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[V03AB09, dimercaprol, Doxepin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AB03, dimethindene, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Doxepin.]
[M02AX03, dimethyl sulfoxide, The metabolism of Doxepin can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Doxepin.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Doxepin can be decreased when combined with Diosmin.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Doxepin.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Doxepin is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C09AA06, quinapril, Doxepin may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Doxepin.]
[N06BA11, dexmethylphenidate, The serum concentration of Doxepin can be increased when it is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A03FA02, cisapride, The metabolism of Doxepin can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Doxepin may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Doxepin.]
[S01AX06, resorcinol, Doxepin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Doxepin may decrease the hypoglycemic activities of Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Doxepin.]
[S02AA12, rifamycin SV, The metabolism of Doxepin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Doxepin can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05AX08, risperidone, Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Doxepin.]
[L01EX01, sunitinib, Doxepin may decrease the hypoglycemic activities of Sunitinib.]
[A04AD12, aprepitant, The metabolism of Doxepin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Doxepin.]
[J05AE07, fosamprenavir, Doxepin can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Doxepin.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Ketorolac.]
[C02KX02, ambrisentan, Doxepin may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Doxepin can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Salsalate.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Doxepin.]
[H05BA01, salmon calcitonin, The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Doxepin.]
[C01CA07, dobutamine, Doxepin may increase the vasopressor activities of Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Doxepin.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Doxepin.]
[N06AA16, dothiepin, The metabolism of Doxepin can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Doxepin.]
[S01AA13, fusidic acid, The metabolism of Doxepin can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Pipemidic acid.]
[N07XX04, sodium oxybate, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Doxepin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxepin can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Doxepin is combined with Sertraline.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Doxepin is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Doxepin can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, The risk or severity of seizure can be increased when Doxepin is combined with Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Doxepin.]
[C09AA11, spirapril, Doxepin may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[V04CX07, edrophonium, The therapeutic efficacy of Doxepin can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, Talinolol may increase the orthostatic hypotensive activities of Doxepin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Tenoxicam.]
[G04CA03, terazosin, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Doxepin can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Doxepin is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may increase the orthostatic hypotensive activities of Doxepin.]
[S01GA02, tetrahydrozoline, Doxepin may increase the vasopressor activities of Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[G04BD01, emepronium, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[G03CX01, tibolone, The serum concentration of Doxepin can be increased when it is combined with Tibolone.]
[C09AA02, enalapril, Doxepin may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the serotonergic activities of Doxepin.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Doxepin.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Doxepin is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Doxepin is combined with Tramazoline.]
[C09AA10, trandolapril, Doxepin may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A03AB08, tridihexethyl, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[G03GA05, follitropin alfa, The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Doxepin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Triptorelin.]
[N04AA12, tropatepine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Doxepin.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C02CA06, urapidil, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.]
[J01MA04, enoxacin, The metabolism of Doxepin can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01CA04, vinorelbine, The metabolism of Doxepin can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Doxepin.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Doxepin is combined with Venlafaxine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Doxepin.]
[S01GA03, xylometazoline, Doxepin may increase the vasopressor activities of Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of hypotension can be increased when Doxepin is combined with Barnidipine.]
[S01EA01, epinephrine, Doxepin may increase the vasopressor activities of Epinephrine.]
[C09AA15, zofenopril, Doxepin may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10AB06, insulin glulisine, human, Doxepin may decrease the hypoglycemic activities of Insulin glulisine.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Doxepin.]
[C01BG01, moricizine, The serum concentration of Doxepin can be increased when it is combined with Moricizine.]
[G02AB03, ergonovine, Doxepin may increase the vasopressor activities of Ergometrine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02CA02, ergotamine, Ergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[L03AX05, pidotimod, Doxepin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Doxepin can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A02BC02, pantoprazole, The metabolism of Doxepin can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Doxepin can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Doxepin can be decreased when combined with Estradiol.]
[G03CC06, estriol, The serum concentration of Doxepin can be increased when it is combined with Estriol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Doxepin can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Doxepin can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Doxepin can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C01CA15, gepefrine, Gepefrine may decrease the sedative and stimulatory activities of Doxepin.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L02AA03, ethinyl estradiol, The metabolism of Doxepin can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Ibutilide.]
[N04AA05, profenamine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Doxepin is combined with Ethylmorphine.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Doxepin.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Doxepin.]
[L01CB01, etoposide, The metabolism of Doxepin can be decreased when combined with Etoposide.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Doxepin.]
[A02BA04, nizatidine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Doxepin.]
[R06AX12, terfenadine, The metabolism of Doxepin can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Doxepin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Doxepin.]
[N06AB08, fluvoxamine, The metabolism of Doxepin can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Doxepin can be decreased when combined with Tocainide.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Leuprolide.]
[M01CB01, gold sodium thiomalate, Doxepin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Doxepin may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Doxepin.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Doxepin can be increased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Doxepin is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Doxepin is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Doxepin is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Fenoprofen.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Doxepin.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Doxepin is combined with Fentanyl.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Doxepin.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[G04BD02, flavoxate, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Doxepin.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Doxepin can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[V03AB25, flumazenil, Doxepin may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[V03AZ01, ethanol, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Doxepin can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Doxepin can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The serum concentration of Doxepin can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Flupentixol may increase the sedative activities of Doxepin.]
[N05AB02, fluphenazine, The serum concentration of Doxepin can be increased when it is combined with Fluphenazine.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Flurbiprofen.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L02BB01, flutamide, The metabolism of Doxepin can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Doxepin.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Doxepin.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[G01AX06, furazolidone, Furazolidone may increase the serotonergic activities of Doxepin.]
[J05AE10, darunavir, The risk or severity of adverse effects can be increased when Darunavir is combined with Doxepin.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Doxepin is combined with Eszopiclone.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Doxepin.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Doxepin is combined with Gallopamil.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N03AA04, barbexaclone, The metabolism of Doxepin can be increased when combined with Barbexaclone.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C10AB04, gemfibrozil, The metabolism of Doxepin can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Degarelix.]
[L01EA02, dasatinib, Doxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Doxepin.]
[A10BJ02, liraglutide, Doxepin may decrease the hypoglycemic activities of Liraglutide.]
[J05AG04, etravirine, The metabolism of Doxepin can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Doxepin is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Lapatinib.]
[A10BB01, glyburide, Doxepin may decrease the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Doxepin may decrease the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Doxepin may decrease the hypoglycemic activities of Glipizide.]
[H04AA01, glucagon, Doxepin may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Doxepin.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Doxepin.]
[C05AE01, nitroglycerin, Doxepin may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Dofetilide.]
[C02CA04, doxazosin, Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[H01AB01, thyrotropin alfa, The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Doxepin.]
[L01EX02, sorafenib, The metabolism of Doxepin can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, Esmolol may increase the orthostatic hypotensive activities of Doxepin.]
[M01CB04, aurothioglucose, Doxepin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Doxepin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Doxepin is combined with Fluindione.]
[C09AA09, fosinopril, Doxepin may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Doxepin may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Doxepin can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Doxepin can be increased when it is combined with Haloperidol.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Histrelin.]
[N05AH04, quetiapine, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine.]
[N06BX13, idebenone, Doxepin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, Doxepin may decrease the hypoglycemic activities of Insulin aspart.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Doxepin.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Doxepin.]
[G03DC01, allylestrenol, Doxepin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The therapeutic efficacy of Mesalazine can be decreased when used in combination with Doxepin.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Doxepin.]
[L01XX03, altretamine, The risk or severity of orthostatic hypotension can be increased when Altretamine is combined with Doxepin.]
[N05CA16, hexobarbital, The metabolism of Doxepin can be increased when combined with Hexobarbital.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Doxepin.]
[J05AG01, nevirapine, The metabolism of Doxepin can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of hypotension can be increased when Doxepin is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Oxatomide.]
[C09AA04, perindopril, Doxepin may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Doxepin may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Doxepin.]
[R05DA03, hydrocodone, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Doxepin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[G04BD06, propiverine, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[B05AA07, hetastarch, Doxepin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Doxepin can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Doxepin.]
[M05BA07, risedronic acid, Doxepin can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Ibuprofen.]
[B05XA08, sodium acetate, Doxepin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, Doxepin may increase the neurotoxic activities of Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Doxepin.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Doxepin.]
[L01AA06, ifosfamide, Doxepin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[H01AC02, somatrem, The metabolism of Doxepin can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Doxepin is combined with Sufentanil.]
[N06AA02, imipramine, Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[L01CD01, paclitaxel, Doxepin may increase the neurotoxic activities of Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Terlipressin.]
[R01AD07, tixocortol, Doxepin may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Doxepin.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Doxepin.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Indomethacin.]
[C02CA02, indoramin, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[A11HA07, inositol, Doxepin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The metabolism of Doxepin can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Doxepin can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Doxepin is combined with Milnacipran.]
[A03AA30, piperidolate, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Doxepin may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BH01, sitagliptin, Doxepin may decrease the hypoglycemic activities of Sitagliptin.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AE01, buclizine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, Doxepin may decrease the hypoglycemic activities of Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Doxepin can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may increase the orthostatic hypotensive activities of Doxepin.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The metabolism of Doxepin can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, Doxepin may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Doxepin.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06AF05, iproniazid, Iproniazid may increase the serotonergic activities of Doxepin.]
[J05AB13, penciclovir, The metabolism of Doxepin can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The serum concentration of Doxepin can be increased when it is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the serotonergic activities of Doxepin.]
[P01AX06, atovaquone, The metabolism of Doxepin can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Doxepin.]
[C09AA16, imidapril, Doxepin may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01EB07, isoflurophate, The therapeutic efficacy of Doxepin can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J04AC01, isoniazid, The metabolism of Doxepin can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Doxepin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Doxepin.]
[A10BJ01, exenatide, Doxepin may decrease the hypoglycemic activities of Exenatide.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Doxepin.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01AA24, kanamycin, Doxepin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The metabolism of Doxepin can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Doxepin can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[B01AC22, prasugrel, Doxepin may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, Doxepin can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AH03, olanzapine, Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Doxepin can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Doxepin can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Mizolastine.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Doxepin.]
[N04BC09, rotigotine, Doxepin may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The metabolism of Doxepin can be decreased when combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Doxepin.]
[C02AA05, deserpidine, Doxepin may decrease the antihypertensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Doxepin.]
[N07AA30, ambenonium, The therapeutic efficacy of Doxepin can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Doxepin.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Doxepin.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Doxepin is combined with Lidoflazine.]
[J01FF02, lincomycin, Doxepin may increase the neurotoxic activities of Lincomycin.]
[S01AA21, amikacin, Doxepin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Doxepin can be decreased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Doxepin is combined with Loperamide.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C10AA02, lovastatin, The metabolism of Doxepin can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Doxepin.]
[L01EG01, temsirolimus, The metabolism of Doxepin can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Doxepin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Doxepin.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Doxepin.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Doxepin can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Doxepin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, Doxepin can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Doxepin.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Meclofenamic acid.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Doxepin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Doxepin.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06DX01, memantine, The metabolism of Doxepin can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Doxepin is combined with Meperidine.]
[C01CA11, mephentermine, Mephentermine may decrease the sedative and stimulatory activities of Doxepin.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N03AA01, mephobarbital, The metabolism of Doxepin can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Doxepin is combined with Meptazinol.]
[G04BX16, tiopronin, Doxepin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The serum concentration of Doxepin can be increased when it is combined with Mesoridazine.]
[N05AX13, paliperidone, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.]
[C01CA09, metaraminol, Doxepin may increase the vasopressor activities of Metaraminol.]
[A10BA02, metformin, Doxepin may decrease the hypoglycemic activities of Metformin.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Doxepin.]
[N06BA03, methamphetamine, Metamfetamine may decrease the sedative and stimulatory activities of Doxepin.]
[A03AB07, methantheline, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[H03BB02, methimazole, The metabolism of Doxepin can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Doxepin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CA15, methohexital, The metabolism of Doxepin can be increased when combined with Methohexital.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Doxepin is combined with Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Doxepin may increase the vasopressor activities of Methoxamine.]
[D05BA02, methoxsalen, The metabolism of Doxepin can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Doxepin.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Doxepin.]
[V04CG05, methylene blue, Doxepin may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Doxepin.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Doxepin.]
[N06BA04, methylphenidate, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Doxepin.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Doxepin.]
[G03EK01, methyltestosterone, Doxepin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Doxepin.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The metabolism of Doxepin can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Doxepin.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Doxepin can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Doxepin.]
[S02AA13, miconazole, The metabolism of Doxepin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Aminophenazone.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01CA17, midodrine, Doxepin may increase the vasopressor activities of Midodrine.]
[G03XB01, mifepristone, Doxepin may decrease the hypoglycemic activities of Mifepristone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Doxepin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Doxepin can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[D11AX01, minoxidil, Doxepin may decrease the antihypertensive activities of Minoxidil.]
[L01XX23, mitotane, The metabolism of Doxepin can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Doxepin.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Doxepin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Doxepin.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Doxepin is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Doxepin can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Doxepin.]
[G04BA01, ammonium chloride, Doxepin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The therapeutic efficacy of Pazopanib can be decreased when used in combination with Doxepin.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CA02, amobarbital, The metabolism of Doxepin can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Doxepin.]
[G04CA04, silodosin, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N06AA17, amoxapine, Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[N03AB05, fosphenytoin, The metabolism of Doxepin can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Doxepin can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, Nadolol may increase the orthostatic hypotensive activities of Doxepin.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N04BC04, ropinirole, Doxepin may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Doxepin can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Doxepin is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Doxepin can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Doxepin is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Doxepin can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Doxepin.]
[N06BA01, amphetamine, Amphetamine may decrease the sedative and stimulatory activities of Doxepin.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Naproxen.]
[A10BG01, troglitazone, Doxepin may decrease the hypoglycemic activities of Troglitazone.]
[N06AX21, duloxetine, The metabolism of Doxepin can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L02BG04, letrozole, The metabolism of Doxepin can be decreased when combined with Letrozole.]
[S03AA01, neomycin, Doxepin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Doxepin is combined with Remifentanil.]
[A10BX02, repaglinide, Doxepin may decrease the hypoglycemic activities of Repaglinide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Levosimendan.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[S01EB06, neostigmine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L03AX16, plerixafor, Doxepin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Doxepin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Doxepin is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Doxepin can be decreased when combined with Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C01CE01, inamrinone, Doxepin may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Doxepin can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the serotonergic activities of Doxepin.]
[C08CA04, nicardipine, Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[C04AE02, nicergoline, Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[P02DA01, niclosamide, The metabolism of Doxepin can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Doxepin.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Doxepin is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of hypotension can be increased when Doxepin is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Doxepin is combined with Nisoldipine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Doxepin is combined with Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N04BC05, pramipexole, Doxepin may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Doxepin may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01CA03, norepinephrine, Doxepin may increase the vasopressor activities of Norepinephrine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Doxepin.]
[C02KX01, bosentan, The metabolism of Doxepin can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Doxepin.]
[R05DA07, noscapine, The metabolism of Doxepin can be decreased when combined with Noscapine.]
[L03AB07, interferon beta-1a, The metabolism of Doxepin can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Doxepin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxepin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Doxepin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Doxepin can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Doxepin is combined with Opium.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Doxepin.]
[G04CA02, tamsulosin, Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[V08CB01, ferumoxsil, Doxepin can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P02BA02, oxamniquine, The metabolism of Doxepin can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Doxepin can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Oxprenolol may increase the orthostatic hypotensive activities of Doxepin.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Doxepin is combined with Oxycodone.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Doxepin.]
[S01GA04, oxymetazoline, Doxepin may increase the vasopressor activities of Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Doxepin is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxepin.]
[N05AH05, asenapine, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M03AC01, pancuronium, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, Doxepin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Papaverine.]
[N05CC05, paraldehyde, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the serotonergic activities of Doxepin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Doxepin.]
[G04BD11, fesoterodine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the orthostatic hypotensive activities of Doxepin.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J01CE09, penicillin G procaine, Doxepin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Doxepin is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Doxepin can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Doxepin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The metabolism of Doxepin can be decreased when combined with Pentoxifylline.]
[N05AB10, perazine, The serum concentration of Doxepin can be increased when it is combined with Perazine.]
[N04BC02, pergolide, Doxepin may increase the vasopressor activities of Pergolide.]
[C08EX02, perhexiline, The metabolism of Doxepin can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The serum concentration of Doxepin can be increased when it is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Doxepin.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Doxepin is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the serotonergic activities of Doxepin.]
[A10BA01, phenformin, Doxepin may decrease the hypoglycemic activities of Phenformin.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Doxepin is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Doxepin can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Doxepin.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Doxepin is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Doxepin is combined with Phenprocoumon.]
[A08AA01, phentermine, Phentermine may decrease the sedative and stimulatory activities of Doxepin.]
[V03AB36, phentolamine, Phentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Phenylbutazone.]
[S01GA05, phenylephrine, Doxepin may increase the vasopressor activities of Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Doxepin can be decreased when combined with Dexlansoprazole.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Doxepin.]
[N03AB02, phenytoin, The metabolism of Doxepin can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Doxepin can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Physostigmine.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of hypotension can be increased when Doxepin is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Doxepin.]
[C07AA03, pindolol, Pindolol may increase the orthostatic hypotensive activities of Doxepin.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J05AE01, saquinavir, Doxepin can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[P02CB01, piperazine, The metabolism of Doxepin can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The serum concentration of Doxepin can be increased when it is combined with Pipotiazine.]
[N06BX03, piracetam, Doxepin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Doxepin may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Doxepin is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Piroxicam.]
[J01DD16, cefditoren, Doxepin can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Grepafloxacin.]
[N02CX01, pizotyline, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.]
[J05AG02, delavirdine, Doxepin can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C09CA04, irbesartan, Doxepin may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A10BG02, rosiglitazone, Doxepin may decrease the hypoglycemic activities of Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Doxepin.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L04AC08, canakinumab, The metabolism of Doxepin can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Doxepin may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Doxepin can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Doxepin may decrease the hypoglycemic activities of Saxagliptin.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Doxepin is combined with Potassium chloride.]
[V03AB21, potassium iodide, The risk or severity of Cardiac Arrhythmia can be increased when Potassium Iodide is combined with Doxepin.]
[A10AD04, insulin lispro, Doxepin may decrease the hypoglycemic activities of Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Doxepin.]
[C07AB01, practolol, Practolol may increase the orthostatic hypotensive activities of Doxepin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Prajmaline.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[P02BA01, praziquantel, The metabolism of Doxepin can be decreased when combined with Praziquantel.]
[C02CA01, prazosin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Antazoline.]
[M02AA16, feprazone, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Feprazone.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Doxepin is combined with Prenylamine.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[P01BA03, primaquine, The metabolism of Doxepin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Doxepin can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Doxepin can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Doxepin.]
[S01HA05, procaine, Procaine may increase the serotonergic activities of Doxepin.]
[L01XB01, procarbazine, Procarbazine may increase the serotonergic activities of Doxepin.]
[C10AB05, fenofibrate, The metabolism of Doxepin can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The serum concentration of Doxepin can be increased when it is combined with Prochlorperazine.]
[N04AA04, procyclidine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Doxepin can be decreased when combined with Progesterone.]
[N05AA03, promazine, Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[R06AD02, promethazine, The serum concentration of Doxepin can be increased when it is combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Doxepin can be decreased when combined with Propafenone.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A03AB05, propantheline, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.]
[N05CM06, propiomazine, Propiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Romidepsin.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Doxepin is combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may increase the orthostatic hypotensive activities of Doxepin.]
[H03BA02, propylthiouracil, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Doxepin.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[B01AC09, epoprostenol, Doxepin may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Doxepin can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the sedative and stimulatory activities of Doxepin.]
[N05AX12, aripiprazole, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Doxepin is combined with Dalfampridine.]
[A03AB15, diphemanil, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Doxepin can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01BA01, quinidine, Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[P01BC01, quinine, The metabolism of Doxepin can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Doxepin can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Doxepin may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Doxepin can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Doxepin.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Doxepin.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Salicylic acid.]
[S01FA02, scopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N05CA06, secobarbital, The metabolism of Doxepin can be increased when combined with Secobarbital.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Doxepin.]
[N04BD01, selegiline, Selegiline may increase the serotonergic activities of Doxepin.]
[J01GB08, sisomicin, Doxepin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Doxepin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Doxepin.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Doxepin.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[H02CA04, levoketoconazole, The metabolism of Doxepin can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Doxepin is combined with Ipratropium.]
[N06AF04, tranylcypromine, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
